

COMMONWEALTH OF MASSACHUSETTS
SUPREME JUDICIAL COURT

Suffolk, SS

No. SJC-2020-757

COMMITTEE FOR PUBLIC COUNSEL SERVICES and MASSACHUSETTS
ASSOCIATION OF CRIMINAL DEFENSE LAWYERS,
Plaintiffs,

v.

BARNSTABLE COUNTY SHERIFF'S OFFICE, BERKSHIRE COUNTY SHERIFF'S
OFFICE, BRISTOL COUNTY SHERIFF'S OFFICE, DUKES COUNTY SHERIFF'S OFFICE,
ESSEX COUNTY SHERIFF'S DEPARTMENT, FRANKLIN COUNTY SHERIFF'S OFFICE,
HAMPDEN COUNTY SHERIFF'S DEPARTMENT, HAMPSHIRE COUNTY SHERIFF'S
OFFICE, MIDDLESEX SHERIFF'S OFFICE, NORFOLK SHERIFF'S OFFICE, PLYMOUTH
COUNTY SHERIFF'S DEPARTMENT and WORCESTER COUNTY SHERIFF'S OFFICE,
Defendants.

AFFIDAVIT OF ALYSSE G. WURCEL

I, Alysse G. Wurcel, MD, MS, hereby depose and state the following:


1. I make the following statements herein based on my personal knowledge.
2. I am a physician licensed to practice internal medicine and infectious diseases (ID) in Massachusetts. I am a licensed buprenorphine prescriber.
3. Currently, I am an Assistant Professor at Tufts Medical Center's Department of Medicine, Division of Geographic Medicine and Infectious Diseases. My CV is attached as Exhibit 1.
4. I am the ID doctor in 5 Massachusetts' jails: Essex, Middlesex, Norfolk, Plymouth, South Bay-Suffolk. I have been working as an ID doctor in jails since 2015.
5. I have over 60 publications in peer-reviewed journals and my research has been focused in improving the quality of health care for people with HIV, people who are incarcerated, and people who use drugs. The first article I published in October 2002 is about the impact of influenza vaccine on people with HIV who are incarcerated.

6. I receive research funding from the Agency for Healthcare Research and Quality aimed at understanding and improving infectious diseases healthcare delivery in jails.
7. I have been working with the Massachusetts Sheriffs' Association (MSA) to provide guidance on COVID-19 best practices and policies in all correctional facilities operated by the fourteen (14) County Sheriffs of the Commonwealth of Massachusetts.
8. I have worked closely with the MSA since April 2020. As several of the county facilities experienced clusters of infection, I worked alongside the Department of Public Health (DPH) to develop testing and mitigation strategies. Since April 2020, the Sheriffs' testing strategies have been in response to recommendations from the DPH. Currently, county facilities test people who are symptomatic and those asymptomatic people identified as potentially exposed. Some county facilities testing all new incarcerated individuals, symptomatic or not, upon intake. In addition, county facilities test people before sending them to certain community programs, or for medical care at outside facilities, and for several other reasons.
9. I have reviewed the scientific studies and literature cited by Plaintiffs' experts. I have not discounted these scientific findings. However, since the beginning of the pandemic there have been numerous manuscripts published about public health interventions aimed at controlling COVID-19. The role of guideline agencies, like the Center for Disease Control and Prevention (CDC) and DPH, is to gather experts dedicated to reviewing the available scientific literature generated in this rapidly developing area of study, and to incorporate these developments into the guidance the agency provides. The CDC is the leading authority for COVID19 prevention and mitigation—including testing—in correctional facilities.
10. For the past year, I have been available for the county facilities to discuss their COVID-19 mitigation and prevention strategies. If the various Sheriffs' Offices had questions about potential infections or clusters of infection, I was available to help provide guidance about testing, quarantine, and isolation.
11. The CDC has periodically issued guidelines for corrections since the beginning of the epidemic, and issued its most recent update on March 17, 2021. I have reviewed the new guidelines, *Interim Guidance for SARS-CoV-2 Testing in Correctional and Detention Facilities*.
12. Under the subheading "Considerations for Different Testing Scenarios," the March 17th CDC guidelines discusses screening testing which including (1) Testing based on movement between facilities and between the facility and the community (2) Expanded screening testing and (3) Serial screening testing for all or a random sample of incarcerated persons. The screening recommendations are a tiered approach, with each tier increasing in intensity and scope. That being said, they are recommendations and in discussions with the CDC they suggested we use their guidelines as recommendations,

and inform decisions for the jails based on factors including but not limited to contact tracing, vaccination rates, community COVID19 incidence, and current volume of tests being set weekly.

13. If at any time DPH were to recommend serial screening testing (facility wide repetitive testing), I would assist the correctional facilities in recommending and implementing these new protocols.
14. On April 4, 2021 I spoke with Robin MacGowan, MPH from the CDC about the updated March 17, 2021 CDC guidelines, *Interim Guidance for SARS-CoV-2 Testing in Correctional and Detention Facilities*. He said that these guidelines do not mandate correctional facilities institute facility wide repetitive COVID-19 testing of inmates; rather, said guidelines only state that such testing may be considered.

SIGNED UNDER THE PAINS AND PENALTIES OF PERJURY THIS
5th DAY OF MAY 2021.



Alysse G. Wurcel, MD, MS

**TUFTS UNIVERSITY SCHOOL OF MEDICINE
CURRICULUM VITAE AND BIBLIOGRAPHY**

April 2021

Alyse Gail Wurcel MD MS

Assistant Professor

Department of Medicine, Tufts Medical Center

Division of Geographic Medicine and Infectious Diseases

800 Washington Street,

Boston, MA 02111

Phone (617) 636-5114

Fax (617) 636-7010

awurcel@tuftsmedicalcenter.org

alysse.wurcel@tufts.edu

EDUCATION

Undergraduate:

2000 BA Tufts University (magna cum laude)

Medical School and/or Graduate School

2008 M.D. University of Pennsylvania School of Medicine

2014 MS Tufts University Graduate School of Biomedical Sciences

POSTDOCTORAL TRAINING

Internship and Residencies:

2008-2011 Internship and Residency in Internal Medicine Massachusetts General Hospital, MA

Fellowships:

2011-2012 Infectious Diseases Columbia-Presbyterian Hospital, New York

2012-2014 Infectious Diseases Tufts Medical Center, MA

LICENSURE AND CERTIFICATION

2014- Commonwealth of Massachusetts License # 245951

2014- Responsible Conduct of Research

2017- Buprenorphine Waiver Training Certification

BOARD CERTIFICATIONS

2011- Diplomate, American Board of Internal Medicine

2013- Diplomate, American Board of Infectious Diseases

ACADEMIC APPOINTMENTS

2014 Clinical Instructor, Tufts University School of Medicine

2015 Assistant Professor, Tufts University School of Medicine

2015 Assistant Professor, Department of Public Health and Community Medicine, Tufts University School of Medicine

HOSPITAL APPOINTMENTS

2014- Infectious Diseases Doctor, Tufts Medical Center

2014- Infectious Diseases Doctor, Lemuel Shattuck Hospital

Wurcel AG Curriculum Vitae /Bibliography

2014-2018	Infectious Diseases Doctor, Beverly Hospital 2014
2016	Infectious Diseases Doctor, Middlesex County Jail
2016	Infectious Diseases Doctor, Essex County Jail
2016	Infectious Diseases Doctor, South Bay Suffolk County Jail
2018-2021	Infectious Diseases Doctor, Bristol County Jail
2019	Infectious Diseases Doctor, Plymouth County Jail
2019	Infectious Diseases Doctor, Norfolk County Jail

ADMINISTRATIVE APPOINTMENTS

2020-	Infectious Diseases Liaison to Mass. Sheriffs Association
2017-2018	Tufts Medical Center Graduate Medical Education. Addiction Curriculum Coordinator
2017-2018	Monthly ID Department Journal Club Coordinator
2018-2019	Intern Support Group Attending
2017-2020	Monthly ID Department Research Meeting Coordinator

AWARDS, HONORS AND NAMED LECTURER:

2000	<i>Magna cum laude</i> , Tufts University
2013	Fellow Immersion Training (FIT) in Addiction Medicine
2013	Julie Guilbert Maher MD Aware for Excellence in Outpatient Care
2013-2015	NIH Loan Repayment Program, NIDDK
2014	Maxwell Finland Award for Research Excellence, Massachusetts Infectious Diseases Society
2014	Edward H. Kass Award for Clinical Excellence, Massachusetts Infectious Diseases Society
2014	Travel Grant, HIV and Liver Disease Conference
2014	Travel Grant, Infectious Diseases Society of America
2015	Dedication to Service Award, Healing Our Community Collaborative, Inc
2015-2016	Top Lecturer, Tufts University School of Medicine
2017-2019	NIH Loan Repayment Program, Health Disparities Research

COMMITTEE ASSIGNMENTS:

Tufts Medical Center

2017-	Opioid Working Group, Tufts Medical Center
2017-2018	Pain Management Committee, Tufts Medical Center

National

2018-	Infectious Diseases Society of America Opioid Task Force
-------	--

NIH and Federal Study Section

2020-	AHRQ Ryan White HIV/AIDS Program services for justice-involved people with HIV
-------	--

Foundation Review

2021-	New Frontiers in Research Fund, Social Sciences and Humanities Research of Canada
-------	---

External Advisory Board

None

Consulting

2017-2019	Course Director, eHIV Review
2018-2020	Gensler Architectural Firm ((Master Plan for Long Island Drug Rehab Center)

2018-2020 Dynamed
2020 Boston Hope Convention Center COVID-19 Infectious Diseases Consultant

TRAINING OF GRADUATE STUDENTS/POST DOCTORAL

URM faculty denoted with *

2020-	Zahna Bingham*	Race Impact on Mortality in People Incarcerated and Hospitalized
2020-	Nicole Cassarino	Multiple Methods Influenza Vaccination Analysis in Jails
2020-	Rachel Jackson*	Perceptions of Race Disparities and COVID19 Testing in Jails
2020-	Mingrui Wei	Racial Disparities in HIV Testing in Inpatients with Substance Use
2020-	Christina Kraus	Vaccine Roll-out in Jails Survey
2020-	Laura Lodolo	Opt-out Infectious Diseases Testing in Jails
2020-	Cody Ellis	Disparities in surgeons reporting to registry of Motor Vehicles
2020-	Max J Nguemeni Tiako*	Influenza preparedness in jails and prisons
2019-	Jessica Penney MD	Outpatient ID clinic
2019-	Yoellys Morales*	Stakeholder views on PICC lines in PWID
2019-	Meagan Murphy	HIV testing in people with substance use disorder
2018-2021	Sarah Khorasani	Linkage of people released from jail to HIV care
2019-2020	Kelly Troosian MD MPH	Naltrexone use in jails
2019-2020	Anna Winston MD MPH	Hepatitis C prevention protocols for dialysis centers
2019-2020	Michelle Ngeouyang	Barrier to HIV testing for inpatients
2019-2020	Jac Carreiro	Flu vaccination rates in MA jails
2018-2020	Jimmy Chen MBS	Infectious diseases testing on intake to MA jails
2017-2020	Gabrielle Horner MPH	Nurses perspectives on people with opioid use disorder
2017-2020	Sun Yu MBS	Implementation of pain and addiction protocol in inpatient setting
2017-2018	Jackie Hodges MD MPH	Hepatitis C treatment in shared treatment model
2017-2018	Brian Engle MD MPH	Impact of HCV on readmission
2017-2019	Whitney Perry MD	ID Fellow, outpatient clinic
2017-2019	Jessica Reyes MD, MPH*	Stakeholder views on HCV care in jails
2017-2019	Ryan Hall MD	Systematic review of surgery outcomes for endocarditis
2017-2019	Michael Shaughnessy	Systematic review of surgery outcomes for endocarditis
2016-2018	Jordan Anderson, BA	Endocarditis in people who use drugs
2016-2017	Paula Grasberger BS	HCV screening in ID clinic
2016-2017	Rosemary Fitzpatrick PA	HCV screening in ID clinic
2016-2017	Michael Goulart, MPH	Shigellosis in Men who have sex with men
2016-2017	Dan Chen MPH	HCV screening in ID outpatient clinic
2015-2020	Elise Merchant MD	Hospitalization outcomes for people who use drugs

TEACHING RESPONSIBILITIES

2012-2014 Infectious diseases lectures (Endocarditis, HIV, Antibiotics) for 4th year medical students
2016 HCV and Pregnancy, OBGYN department
2016-2017 Ethics small group leader,
2016-2017 HIV and LGBT issues, dental students
2016-2019 Hepatitis C treatment, ID fellows
2017-2018 Fever, 2nd year medical students
2017- Parasites, 2nd year medical students
2018- Acute Hepatitis, 3rd year medical students
2018-2020 Pneumonia, Internal Medicine residents
2019- Skin and soft tissue infections in people who use drugs, Internal Medicine Residents

2020- Endocarditis, Internal Medicine residents

MEMBERSHIPS, OFFICES, PROFESSIONAL SOCIETIES

2008- Member, Massachusetts Medical Society
2011- Member, Infectious Diseases Society of
2012-2013 Member, American Association for the Study of Liver Diseases
2017- Member, HIV Medical Association

RESEARCH SUPPORT

Federal Grants

Grant Title: The Economic Burden of HIV and HCV Infection in Hospitalized Inmate
Funding Agency: Center for AIDS Research, NIAID P30AIO42853
Amount: \$50,000 (0.15 FTE)
Period: 2/2016-2/2017
Role: Principal Investigator

Grant Title: Substance Abuse Expansion Package
Funding Agency: HRSA-16-074
Amount: \$45,000 (0.1 FTE)
Period: July 2016-July 2018
Role: Consultant

Grant Title: Characterizing HIV-related Diastolic Dysfunction
Funding Agency: Subcontract from Duke NIH/NHLB 5U10HL084904-11
Period: 11/1/2016 – 10/31/2018
Role: Study Site Co-Investigator

Grant Title: KL2: Unlocking HCV care in Jails: Stakeholders hold the key
Funding Agency: Tufts CTSI KL2-TR002545-10
Amount: \$250,000
Period: May 2018- April 2020

Grant Title: K08: Unlocking HCV care in Jails: Stakeholders hold the key
Funding Agency: AHRQ K08-HS026008-01A1
Amount: \$449,528
Period: May 2020- April 2023

State and Local Grants

Grant Title: Intestinal Permeability in People with HIV and HCV
Funding Agency: Natalie Zucker Research Award, Tufts University School of Medicine
Amount: \$5000
Period: 2013
Role: Principal Investigator

Grant Title: Tufts Responds to the Epidemics of Addiction and Hepatitis C Together
Funding Agency: Tufts Institute for Innovation Grant
Amount: \$250,000 (0.1 FTE)
Period: 7/1/2015-6/30/2016
Role: Co-Investigator

Grant Title: “Health Services and Systems Science Assessment of HIV Inmate-to-Community Care Transitions”

Funding Agency: Tufts University Clinical and Translational Institute

Amount: \$60,000 (10,000 towards salary)

Period: 5/1/2018-4/30/2019

Role: Co-Investigator

Grant Title: Health Care Workers Disparities in COVID testing

Funding Agency: Tufts Medical Center/Tufts University School of Medicine

Amount: \$50,000

Period: 5/1/2020-4/30/2021

Role: Principal Investigator

Grant Title: HIV Testing at Tufts Medical Center

Funding Agency: Tufts University Substance Use Disorder Grant

Amount: \$25,000

Period: 5/1/2020-4/30/2021

Role: Principal Investigator

Other Grants

Grant Title: Quality Improvement Initiative: Improving HCV Screening rates and Management of HIV/HCV patients in an urban academic medical center

Funding Agency: Merck

Amount: \$30,000

Period: 09/01/14 – 06/30/16

Role: Study Site Co-Investigator

Grant Title: Is HCV in Inmates a Predictor of Readmission to the Hospital? A Multivariable Analysis and Assessment of Costs associated with Readmission

Funding Agency: Bristol-Myers-Squibb Fellows Virology Grant

Amount: \$15,000

Period: 02/01/15-08/30/16

Role: Principal Investigator

G

Grant Title: “A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to investigate the Efficacy and Safety of BMS-663068/GSK3684934 in Heavily Treatment Experienced Subjects infected with Multi-drug Resistant HIV-1”

Funding Agency: AI438047/205888, ViiV Healthcare United Limited

Period: 06/2015 – ongoing

Role: Site Principal Investigator

Grant Title Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE

Funding Agency: 5U01HL123336-04, NIH/NHLBI

Period: 5/1/16-ongoing

Role: Site Principal Investigator

Grant Title: Interest in PrEP in Jailed Populations

Funding Agency: Merck

Amount: \$100,000 (FTE 0.03)

Period: 1/1/2020-12/31/2021

Role: Co-Investigator

Grant Title: HIV Testing at Tufts Medical Center

Funding Agency: Tufts University Substance Use Disorder Grant

Amount: \$25,000

Period: 5/1/2020-4/30/2021

Role: Principal Investigator

EDITORIAL BOARDS AND ACTIVITY

2020 Open Forum Infectious Diseases

BIBLIOGRAPHY

A.) PAPERS

Stone DR, Corcoran C, Wurcel A, McGovern B, Quirk J, Brewer A, Sutton L, D'Aquila RT. Antiretroviral drug resistance mutations in antiretroviral-naive prisoners. *Clin Infect Dis*. 2002 Oct 1;35(7):883-6. doi: 10.1086/342697. Epub 2002 Sep 11. PMID: 12228827.

Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, Chung RT, Walker BD. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. *J Virol*. 2002 Dec;76(24):12584-95. doi: 10.1128/jvi.76.24.12584-12595.2002. PMID: 12438584; PMCID: PMC136690.

Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgoz N, Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, Walker BD. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. *J Virol*. 2003 Feb;77(3):2081-92. doi: 10.1128/jvi.77.3.2081-2092.2003. PMID: 12525643; PMCID: PMC140965.

Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, Wurcel AG, Stone DR, Kalams SA, Trocha A, Addo MM, Goulder PJ, Walker BD. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. *J Immunol Methods*. 2003 Apr 1;275(1-2):19-29. doi: 10.1016/s0022-1759(02)00541-0. PMID: 12667667.

Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, Corcoran CP, Szczepiorkowski Z, Toner S, Cohen DE, Sax PE, Ukumadu C. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. *Clin Infect Dis*. 2003 Jun 15;36(12):1602-5. doi: 10.1086/375084. Epub 2003 Jun 6. Erratum in: *Clin Infect Dis*. 2003 Jul 1;37(1):157. PMID: 12802762.

Gandhi RT, Wurcel A, McGovern B, Lee H, Shopis J, Corcoran CP, Toner S, Giachetti C, Dockter J, Sax PE, Ukumadu C. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody

to hepatitis B core antigen. *J Acquir Immune Defic Syndr*. 2003 Dec 1;34(4):439-41. doi: 10.1097/00126334-200312010-00013. PMID: 14615664.

Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, Hirsch MS, Walker BD. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. *Clin Infect Dis*. 2003 Dec 15;37(12):1693-8. doi: 10.1086/379773. Epub 2003 Nov 17. PMID: 14689353.

Draenert R, Verrill CL, Tang Y, Allen TM, Wurcel AG, Boczanowski M, Lechner A, Kim AY, Suscovich T, Brown NV, Addo MM, Walker BD. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. *J Virol*. 2004 Jan;78(2):630-41. doi: 10.1128/jvi.78.2.630-641.2004. PMID: 14694094; PMCID: PMC368768.

Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, Addo MM, Feeney ME, Yusim K, Sango K, Brown NV, SenGupta D, Piechocka-Trocha A, Simonis T, Marincola FM, Wurcel AG, Stone DR, Russell CJ, Adolf P, Cohen D, Roach T, StJohn A, Khatri A, Davis K, Mullins J, Goulder PJ, Walker BD, Brander C. Consistent cytotoxic-T- lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. *J Virol*. 2004 Mar;78(5):2187-200. doi: 10.1128/jvi.78.5.2187-2200.2004. PMID: 14963115; PMCID: PMC369231.

Yu XG, Addo MM, Perkins BA, Wej F, Rathod A, Geer SC, Parta M, Cohen D, Stone DR, Russell CJ, Tanzi G, Mei S, Wurcel AG, Frahm N, Lichterfeld M, Heath L, Mullins JI, Marincola F, Goulder PJ, Brander C, Allen T, Cao Y, Walker BD, Altfeld M. Differences in the expressed HLA class I alleles effect the differential clustering of HIV type 1-specific T cell responses in infected Chinese and caucasians. *AIDS Res Hum Retroviruses*. 2004 May;20(5):557-64. doi: 10.1089/088922204323087813. PMID: 15186531.

Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, Cohen D, Robbins GK, Pae E, Alter G, Wurcel A, Stone D, Rosenberg ES, Walker BD, Altfeld M. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. *J Exp Med*. 2004 Sep 20;200(6):701-12. doi: 10.1084/jem.20041270. PMID: 15381726; PMCID: PMC2211961.

Kim AY, Lauer GM, Ouchi K, Addo MM, Lucas M, Schulze Zur Wiesch J, Timm J, Boczanowski M, Duncan JE, Wurcel AG, Casson D, Chung RT, Draenert R, Klenerman P, Walker BD. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfecting with HIV-1. *Blood*. 2005 Feb 1;105(3):1170-8. doi: 10.1182/blood-2004-06-2336. Epub 2004 Sep 30. PMID: 15459014.

Gandhi RT, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, Sivamurthy R, Sax PE, Ukomadu C. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. *J Infect Dis*. 2005 May 1;191(9):1435-41. doi: 10.1086/429302. Epub 2005 Mar 28. PMID: 15809901.

Frahm N, Adams S, Kiepiela P, Linde CH, Hewitt HS, Lichterfeld M, Sango K, Brown NV, Pae E, Wurcel AG, Altfeld M, Feeney ME, Allen TM, Roach T, St John MA, Daar ES, Rosenberg E, Korber B, Marincola F, Walker BD, Goulder PJ, Brander C. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte

epitopes and is associated with low human immunodeficiency virus load. *J Virol.* 2005 Aug;79(16):10218-25. doi: 10.1128/JVI.79.16.10218-10225.2005. PMID: 16051815; PMCID: PMC1182636.

Wurcel A, Zaman T, Zhen S, Stone D. Acceptance of HIV antibody testing among inpatients and outpatients at a public health hospital: a study of rapid versus standard testing. *AIDS Patient Care STDS.* 2005 Aug;19(8):499-505. doi: 10.1089/apc.2005.19.499. PMID: 16124844.

Schulze zur Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE, Wurcel AG, Timm J, Jones AM, Mothe B, Allen TM, McGovern B, Lewis-Ximenez L, Sidney J, Sette A, Chung RT, Walker BD. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. *J Immunol.* 2005 Sep 15;175(6):3603-13. doi: 10.4049/jimmunol.175.6.3603. PMID: 16148104.

Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, Feeney ME, Addo MM, Lichterfeld M, Lahaie MP, Pae E, Wurcel AG, Roach T, St John MA, Altfeld M, Marincola FM, Moore C, Mallal S, Carrington M, Heckerman D, Allen TM, Mullins JI, Korber BT, Goulder PJ, Walker BD, Brander C. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. *Nat Immunol.* 2006 Feb;7(2):173-8. doi: 10.1038/ni1281. Epub 2005 Dec 20. PMID: 16369537.

Ancuta P, Autissier P, Wurcel A, Zaman T, Stone D, Gabuzda D. CD16+ monocyte-derived macrophages activate resting T cells for HIV infection by producing CCR3 and CCR4 ligands. *J Immunol.* 2006 May 15;176(10):5760-71. doi: 10.4049/jimmunol.176.10.5760. PMID: 16670281.

McGovern BH, Wurcel A, Kim AY, Schulze zur Wiesch J, Bica I, Zaman MT, Timm J, Walker BD, Lauer GM. Acute hepatitis C virus infection in incarcerated injection drug users. *Clin Infect Dis.* 2006 Jun 15;42(12):1663-70. doi: 10.1086/504327. Epub 2006 May 11. PMID: 16705568.

Corey KE, Ross AS, Wurcel A, Schulze Zur Wiesch J, Kim AY, Lauer GM, Chung RT. Outcomes and treatment of acute hepatitis C virus infection in a United States population. *Clin Gastroenterol Hepatol.* 2006 Oct;4(10):1278-82. doi: 10.1016/j.cgh.2006.06.026. Epub 2006 Aug 22. PMID: 16931171; PMCID: PMC1828916.

Kim AY, Schulze zur Wiesch J, Kuntzen T, Timm J, Kaufmann DE, Duncan JE, Jones AM, Wurcel AG, Davis BT, Gandhi RT, Robbins GK, Allen TM, Chung RT, Lauer GM, Walker BD. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. *PLoS Med.* 2006 Dec;3(12):e492. doi: 10.1371/journal.pmed.0030492. PMID: 17194190; PMCID: PMC1705826.

Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT, Robbins GK, Basgoz NO, Stone DR, Cohen DE, Johnston MN, Flynn T, Wurcel AG, Rosenberg ES, Altfeld M, Walker BD. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. *PLoS One.* 2007 Mar 28;2(3):e321. doi: 10.1371/journal.pone.0000321. PMID: 17389912; PMCID: PMC1824710.

Schulze Zur Wiesch J, Lauer GM, Timm J, Kuntzen T, Neukamm M, Berical A, Jones AM, Nolan BE, Longworth SA, Kasprovicz V, McMahon C, Wurcel A, Lohse AW, Lewis-Ximenez LL, Chung RT, Kim AY, Allen TM, Walker BD. Immunologic evidence for lack of heterologous protection following resolution of HCV

in patients with non-genotype 1 infection. *Blood*. 2007 Sep 1;110(5):1559-69. doi: 10.1182/blood-2007-01-069583. Epub 2007 May 2. PMID: 17475911; PMCID: PMC1975840.

Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. *PLoS One*. 2008 Jun 25;3(6):e2516. doi: 10.1371/journal.pone.0002516. PMID: 18575590; PMCID: PMC2424175.

McNairy ML, Wurcel AG, Huang F, Daily JP. Health care workers in Africa access a broad range of topics using evidence-based online medical information. *Glob Public Health*. 2012;7(8):823-39. doi: 10.1080/17441692.2012.685488. Epub 2012 May 23. PMID: 22621407.

Sung S, Wurcel AG, Whittier S, Kulas K, Kramer LD, Flam R, Roberts JK, Tsiouris S. Powassan meningoencephalitis, New York, New York, USA. *Emerg Infect Dis*. 2013;19(9):1549-51. doi: 10.3201/eid1909.121846. PMID: 23969017; PMCID: PMC3810908.

Taylor LE, Foont JA, DeLong AK, Wurcel A, Linas BP, Chapman S, Maynard MA, Cu-Uvin S, Mayer KH. The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic. *AIDS Patient Care STDS*. 2014 Jan;28(1):4-9. doi: 10.1089/apc.2013.0130. PMID: 24428794; PMCID: PMC3894677.

Wurcel AG, Chen DD, Fitzpatrick RE, Grasberger PE, Kirshner CH, Anderson JE, Chui KK, Knox TA. Hepatitis C Screening in People With Human Immunodeficiency Virus: Lessons Learned From Syphilis Screening. *Open Forum Infect Dis*. 2016 Feb 12;3(1):ofv215. doi: 10.1093/ofid/ofv215. PMID: 26885544; PMCID: PMC4751919.

Goulart MA, Wurcel AG. Shigellosis in men who have sex with men: an overlooked opportunity to counsel with pre-exposure prophylaxis for HIV. *Int J STD AIDS*. 2016 Nov;27(13):1236-1238. doi: 10.1177/0956462416638609. Epub 2016 Mar 4. PMID: 26945593.

Wurcel AG, Anderson JE, Chui KK, Skinner S, Knox TA, Snyderman DR, Stopka TJ. Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs. *Open Forum Infect Dis*. 2016 Jul 26;3(3):ofw157. doi: 10.1093/ofid/ofw157. PMID: 27800528; PMCID: PMC5084714.

Mukerji SS, Misra V, Lorenz D, Cervantes-Arslanian AM, Lyons J, Chalkias S, Wurcel A, Burke D, Venna N, Morgello S, Koralknik IJ, Gabuzda D. Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults. *J Acquir Immune Defic Syndr*. 2017 Jun 1;75(2):246-255. doi: 10.1097/QAI.0000000000001362. PMID: 28328546; PMCID: PMC5452976.

Wurcel AG, Chen DD, Chui KKH, Knox TA. "Tweak Your Order Set!" Implementation of Modified Laboratory Order Set Improves Hepatitis C Virus Screening Rates in People Living With Human Immunodeficiency Virus. *Open Forum Infect Dis*. 2017 May 16;4(2):ofx098. doi: 10.1093/ofid/ofx098. PMID: 28852673; PMCID: PMC5569929.

Goulart MA, Wurcel AG, Stopka TJ. Investigating the Geographic Distribution of Shigellosis Among Men and Women in Massachusetts: Possible Implications for Men Who Have Sex With Men. *Sex Transm Dis*. 2018 Mar;45(3):183-185. doi: 10.1097/OLQ.0000000000000711. PMID: 29420446.

Wurcel AG, Burke D, Skeer M, Landy D, Heimer R, Wong JB, Chui KKH, Stopka TJ. Sex work, injection drug use, and abscesses: Associations in women, but not men. *Drug Alcohol Depend.* 2018 Apr 1;185:293-297. doi: 10.1016/j.drugalcdep.2017.12.028. Epub 2018 Feb 20. PMID: 29482054; PMCID: PMC5991097.

Oh DHW, Wurcel AG, Tybor DJ, Burke D, Menendez ME, Salzler MJ. Increased Mortality and Reoperation Rates After Treatment for Septic Arthritis of the Knee in People Who Inject Drugs: Nationwide Inpatient Sample, 2000-2013. *Clin Orthop Relat Res.* 2018 Aug;476(8):1557-1565. doi: 10.1097/01.blo.0000534682.68856.d8. PMID: 29762153; PMCID: PMC6259777.

Wurcel AG, Burke DJ, Wang JJ, Engle B, Noonan K, Knox TA, Kim AY, Linas BP. The Burden of Untreated HCV Infection in Hospitalized Inmates: a Hospital Utilization and Cost Analysis. *J Urban Health.* 2018 Aug;95(4):467-473. doi: 10.1007/s11524-018-0277-z. PMID: 30027427; PMCID: PMC6095754.

Hodges J, Reyes J, Campbell J, Klein W, Wurcel A. Successful Implementation of a Shared Medical Appointment Model for Hepatitis C Treatment at a Community Health Center. *J Community Health.* 2019 Feb;44(1):169-171. doi: 10.1007/s10900-018-0568-z. PMID: 30132236; PMCID: PMC6330118.

Hall R, Shaughnessy M, Boll G, Warner K, Boucher HW, Bannuru RR, Wurcel AG. Drug Use and Postoperative Mortality Following Valve Surgery for Infective Endocarditis: A Systematic Review and Meta-analysis. *Clin Infect Dis.* 2019 Sep 13;69(7):1120-1129. doi: 10.1093/cid/ciy1064. PMID: 30590480; PMCID: PMC6743840.

Wurcel AG, Boll G, Burke D, Khetarpal R, Warner PJ, Tang AM, Warner KG. Impact of Substance Use Disorder on Midterm Mortality After Valve Surgery for Endocarditis. *Ann Thorac Surg.* 2020 May;109(5):1426-1432. doi: 10.1016/j.athoracsur.2019.09.004. Epub 2019 Oct 17. PMID: 31630767; PMCID: PMC7153977.

Horner G, Daddona J, Burke DJ, Cullinane J, Skeer M, Wurcel AG. "You're kind of at war with yourself as a nurse": Perspectives of inpatient nurses on treating people who present with a comorbid opioid use disorder. *PLoS One.* 2019 Oct 24;14(10):e0224335. doi: 10.1371/journal.pone.0224335. PMID: 31648259; PMCID: PMC6812769.

Huang KTL, Blazey-Martin D, Chandler D, Wurcel A, Gillis J, Tishler J. A multicomponent intervention to improve adherence to opioid prescribing and monitoring guidelines in primary care. *J Opioid Manag.* 2019 Nov/Dec;15(6):445-453. doi: 10.5055/jom.2019.0535. PMID: 31850506; PMCID: PMC7787190.

Barocas JA, Morgan JR, Wang J, McLoone D, Wurcel A, Stein MD. Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis. *Clin Infect Dis.* 2021 Feb 1;72(3):472-478. doi: 10.1093/cid/ciaa062. PMID: 31960025; PMCID: PMC7850516.

Toppo AJ, Rogerson A, Oh DHW, Tybor DJ, Wurcel AG, Salzler MJ. Injection Drug Use in Patients With Spinal Epidural Abscess: Nationwide Data, 2000 to 2013. *Spine (Phila Pa 1976).* 2020 Jun 15;45(12):843-850. doi: 10.1097/BRS.0000000000003401. PMID: 32004230.

Merchant E, Burke D, Shaw L, Tookes H, Patil D, Barocas JA, Wurcel AG. Hospitalization outcomes of people who use drugs: One size does not fit all. *J Subst Abuse Treat*. 2020 May;112:23-28. doi: 10.1016/j.jsat.2020.01.010. Epub 2020 Jan 22. PMID: 32199542; PMCID: PMC7089869.

Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHT Trial Team. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. *N Engl J Med*. 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493. PMID: 32212519.

Toppo AJ, Oh DHW, Tybor DJ, Wurcel AG, Menendez ME, Ryan SP, Salzler MJ. Hospital Stays and Medical Expenses Increase Nationwide Among Patients With Septic Arthritis of the Shoulder Who Inject Drugs. *Orthopedics*. 2020 Jul 1;43(4):e270-e277. doi: 10.3928/01477447-20200415-03. Epub 2020 Apr 23. PMID: 32324247.

Wurcel AG, Yu S, Burke D, Lund A, Schelling K, Weingart SN, Freund KM. Implementation of a Patient-Provider Agreement to Improve Healthcare Delivery for Patients With Substance Use Disorder in the Inpatient Setting. *J Patient Saf*. 2020 May 7:10.1097/PTS.0000000000000721. doi: 10.1097/PTS.0000000000000721. Epub ahead of print. PMID: 32398540; PMCID: PMC7785299.

Neilan TG, Nguyen KL, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadalla M, Drobni ZD, Nelson MD, Burdo TH, Van Schalkwyk M, Sax PE, Skiest DJ, Tashima K, Landovitz RJ, Daar E, Wurcel AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaldo H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. *J Infect Dis*. 2020 Jul 9;222(Suppl 1):S63-S69. doi: 10.1093/infdis/jiaa245. PMID: 32645158; PMCID: PMC7347082.

Fichtenbaum CJ, Ribaldo HJ, Leon-Cruz J, Overton ET, Zanni MV, Malvestutto CD, Aberg JA, Kileel EM, Fitch KV, Van Schalkwyk M, Kumarasamy N, Martinez E, Santos BR, Joseph Y, Lo J, Siminski S, Melbourne K, Sponseller CA, Desvigne-Nickens P, Bloomfield GS, Currier JS, Hoffmann U, Douglas PS, Grinspoon SK; REPRIEVE Investigators. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. *J Infect Dis*. 2020 Jul 9;222(Suppl 1):S8-S19. doi: 10.1093/infdis/jiaa259. PMID: 32645162; PMCID: PMC7347081.

Saldana CS, Vyas DA, Wurcel AG. Soft Tissue, Bone, and Joint Infections in People Who Inject Drugs. *Infect Dis Clin North Am*. 2020 Sep;34(3):495-509. doi: 10.1016/j.idc.2020.06.007. PMID: 32782098.

Seval N, Wurcel A, Gunderson CG, Grimshaw A, Springer SA. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons: A Systematic Review. *Infect Dis Clin North Am*. 2020 Sep;34(3):559-584. doi: 10.1016/j.idc.2020.06.011. PMID: 32782102; PMCID: PMC7437982.

Springer SA, Barocas JA, Wurcel A, Nijhawan A, Thakrar K, Lynfield R, Hurley H, Snowden J, Thornton A, Del Rio C. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda. *J Infect Dis*. 2020 Sep 2;222(Suppl 5):S230-S238. doi: 10.1093/infdis/jiz673. PMID: 32877568; PMCID: PMC7467230.

Zubiago J, Murphy M, Guardado R, Daudelin D, Patil D, Wurcel A. Increased HIV testing in people who use drugs hospitalized in the first wave of the COVID-19 pandemic. *J Subst Abuse Treat.* 2021 May;124:108266. doi: 10.1016/j.jsat.2020.108266. Epub 2021 Jan 6. PMID: 33771274; PMCID: PMC7831875.

B.) BOOK CHAPTERS/INVITED REVIEWS

McGovern B, Fiore J, Wurcel A, Taglienti P, Bradley M, Galvin S, Libone G, Ramsey J, Molinaro-Gudas V, Drewniak S, Amick C, Andalkar A, Scheft H, Bica I. Delivering therapy for hepatitis C virus infection to incarcerated HIV- seropositive patients. *Clin Infect Dis.* 2005 Jul 1;41 Suppl 1:S56-62. doi: 10.1086/429497. PMID: 16265615.

Wurcel AG, Merchant EA, Clark RP, Stone DR. Emerging and Underrecognized Complications of Illicit Drug Use. *Clin Infect Dis.* 2015 Dec 15;61(12):1840-9. doi: 10.1093/cid/civ689. Epub 2015 Aug 12. PMID: 26270683; PMCID: PMC4657534.

Winston A, Wurcel AG, Gordon C, Goyal N. Viral hepatitis in patients on hemodialysis. *Semin Dial.* 2020 May;33(3):254-262. doi: 10.1111/sdi.12882. Epub 2020 May 11. PMID: 32394502.

Wurcel AG et al. "Insiders and Outsiders: A Case Study of Fostering Research Partnerships between Academic Health Centers and Corrections Institutions." *Broadly-Engaged Team Science in Clinical and Translational Research.* *In press* Springer Nature Switzerland AG

C.) EDITORIALS AND CONFERENCE PROCEEDINGS

Wurcel AG. To whom shall I tell my grief? *Am J Kidney Dis.* 2013 Nov;62(5):xxv-xxvi. doi: 10.1053/j.ajkd.2013.08.006. PMID: 24157277.

The Tricky Art of Managing Infectious Complications of Addiction: Dr. Paul Sax Interviews Dr. Alysse Wurcel. *Open Forum Infect Dis.* 2017 Dec 4;4(4):ofx190. doi: 10.1093/ofid/ofx190. PMID: 29766013; PMCID: PMC5946887.

Wurcel AG, Yu S, Pacheco M, Warner K. Contracts with people who inject drugs following valve surgery: Unrealistic and misguided expectations. *J Thorac Cardiovasc Surg.* 2017 Dec;154(6):2002. doi: 10.1016/j.jtcvs.2017.07.020. PMID: 29132892.

Wurcel AG. Drug-Associated Infective Endocarditis Trends: What's All the Buzz About? *Ann Intern Med.* 2019 Jan 1;170(1):68-69. doi: 10.7326/M18-3026. Epub 2018 Dec 4. PMID: 30508422; PMCID: PMC6548684.

Wurcel AG. Rise in Endocarditis-Related Hospitalizations in Young People Who Use Opioids: A Call to Action *Clin Infect Dis.* 2020 Apr 9;ciaa376. doi: 10.1093/cid/ciaa376. Online ahead of print.

Wurcel AG, Dauria E, Zaller N, Nijhawan A, Beckwith C, Nowotny K, Brinkley- Rubinstein L. Spotlight on Jails: COVID-19 Mitigation Policies Needed Now. *Clin Infect Dis.* 2020 Jul 28;71(15):891-892. doi: 10.1093/cid/ciaa346. PMID: 32221515; PMCID: PMC7385748.

D.) BOOKS AUTHORED/EDITED

None

E.) ONLINE AND OTHER DISSEMINATED PUBLICATIONS

Wurcel AG. eHIV Review: HIV and Lung Disease. <http://ehivreview.org/newsletters/volume-3/ehiv-volume-3-issue-1.html> Aug 2017

The Tricky Art of Managing Infectious Complications of Addiction: Dr. Paul Sax Interviews Dr. Alysse Wurcel. *Open Forum Infect Dis.* 2017 Dec 4;4(4):ofx190. doi: 10.1093/ofid/ofx190. eCollection 2017 Fall. PubMed PMID: 2976601

Wurcel AG. Is HIV Prevention Feasible in the Correctional Setting? *CorrectCare Magazine* <https://www.exchangeccme.com/HIVCorrections> May 2019

Wurcel AG. The HIV/HCV Syndemic: More than the Sum of Parts. *CorrectCare Magazine* <https://www.exchangeccme.com/HCVCorrections> May 2019

Shafer RA, Grossman KG, Wurcel AG. "Caution Oxcarbazepine and Carbamazepine Interact with Many HIV Medications." Spring 2021. Page 12-13 *CorrectCare Magazine*

F.) PUBLISHED ABSTRACTS

Gandhi RT, Wurcel AG, McGovern B. Low Prevalence of Hepatitis B Viremia in HIV+ Individuals with Isolated Antibody to Hepatitis B Core Antigen (anti-HBc). Presented at 2003 Infectious Disease Society of America Conference, San Francisco. Poster #601

Wurcel AG, Bica I, Gandhi RT, Bradley M, Galvin, RN, MCGovern B. Acute Hepatitis C (HCV) in Incarcerated Patients with a History of Intravenous Drug Use. Presented at 2003 Infectious Disease Society of America Conference, San Francisco. Poster #592

Wurcel AG, Zhen S, Stone DR. Feasibility and Acceptability of Rapid HIV Testing in a Public Health Hospital. Presented at 2004 Infectious Disease Society of America Conference, Boston. Poster #840.

Wurcel A., Lioznov D, Evseeva I., Sizova N, Terekhin Y., Vasilieva T., Metzger D, Frank I. Sexual and Drug-Related Risk Behaviors and Knowledge of HIV Transmission in HIV Infected Individuals in Urban and Suburban St. Petersburg, Russia. Presented at the 2006 International AIDS Conference in Toronto. Poster TUPE0492

Wurcel, A. Sakmar, K. Myxedema Coma: Dramatic Presentation; Simple Cure. Massachusetts Medical Society Annual Meeting, November 2009.

Kim AY, Hills-Evans K, Nagami EH, Reyor LL, Wurcel AG, McGovern BII. Racial differences in drug use behaviors and risk for HCV infection among Massachusetts inmates. AASLD Conference, Boston, MA. November 2011

Taylor LE, Maynard MA, Foont JA, Chapman S, DeLong AK, Wurcel AG, Cu-Uvin S, Maye KHR. The Spectrum of Undiagnosed Hepatitis C Virus (HCV) in a U.S. HIV Clinic. HIV and Liver Diseases Conference, Jackson Hole, Wyoming, September 2012.

Wurcel AG, Perkins R, Chen D, Grasberger P, Kogelman, L, Knox, T. Hepatitis C Screening Quality Improvement Project HIV and Liver Diseases Conference, Jackson Hole, Wyoming, September 2014.

Wurcel AG, Superson M, Noonan K, Onoughfrey, S, Church D, Kim AY, McGovern BM. Burden of Hepatitis C Virus and Infective Endocarditis in Community and Inmate Hospitalized Patients in Massachusetts. IDSA Conference, Philadelphia October 2014 (accepted)

Virgina Lijewski, Michaela Superson, Daniel Church, Alfred Demaria, Alysse Wurcel "Hepatitis C-Related Admissions to a Public Health Hospital and Hepatitis C Reporting to the Massachusetts Department of Public Health - " (ID#4935) Boston MA June 2015 Council of State and Territorial Epidemiologists (CSTE)

Successful implementation of shared medical appointments for HCV treatment in people who are homeless or at risk for homelessness: Lessons from a community health center on Cape Cod. Science of Dissemination and Implementation. Arlington, VA. December 4, 2017

Burke D, Wurcel AG, Skeer M, Heimer R, Chui KKH, Stopka TJ "Sex Work, Injection Drug Use and Abscesses: Associations in Women, But Not Men" Presented at: ID Week 2017

Merchant E, Burke D, Diaz C, Barocas J, Tookes H III, Wurcel A. 1946. Heterogeneous Hospitalization Outcomes of People Who Use Drugs: The Type of Drug(s) Used Matters. *Open Forum Infect Dis.* 2018;5(Suppl 1):S561. Published 2018 Nov 26. doi:10.1093/ofid/ofy210.1602

The Burden of Untreated HCV Infection in Hospitalized Inmates: A Hospital Utilization and Cost Analysis" Academic Consortium on Criminal Justice Health. Houston, TX. December 14, 2018

Wurcel, A., Burke, D., Freund, K., Beckwith, C., & Wong, J. (2019). 3209 Hepatitis C Virus Linked To Increased Mortality in Inmates Who Are Hospitalized. *Journal of Clinical and Translational Science*, 3(S1), 145-145. doi:10.1017/cts.2019.330

Wurcel AG, Reyes J, Zubiago J, et al. 299. "Where the Rubber Meets the Road": Stakeholders' Perspectives about the Current State of HCV Care Delivery in Massachusetts Jails. *Open Forum Infect Dis.* 2019;6(Suppl 2):S161-S162. Published 2019 Oct 23. doi:10.1093/ofid/ofz360.374

Chen G, Reyes J, Nowotny K, Wurcel A. "Heterogeneity in Jail Nursing Medical Intake Forms: A Content Analysis Focusing on Viral Hepatitis, HIV, and Substance Use Disorder" Poster presented at ACCJH, 2019

I.) INVITED LECTURES (2010 to present)

2021

"Infectious Diseases care in Massachusetts jails," Infectious Diseases Grand Rounds, University of Alabama, March 18, 2021

“Infectious Diseases care in Massachusetts jails,” HIV Monthly Conference, March 8 2021

“Ask an Expert: Dialogue on the COVID19 Vaccine with Criminal Justice and Public Health Champions,” Center for Behavioral Health and Justice at Wayne State University. February 25, 2021

2020

“5 Steps to Improving Healthcare for People Who Inject Drugs,” Milton Regional Health Center Grand Rounds, November 19, 2020

“Panel Discussion: Equity in the COVID-19 Pandemic,” Tufts University COVID19 Research Symposium, November 18, 2020

“COVID 19 in MA Jails,” National Commission on Correctional Health Care Webinar, September 2020

“COVID 19 in MA Jails,” Massachusetts Consortium of Pathogen Readiness Public Briefing September 2020

“COVID-19 Press Briefing”, Reform Alliance Webinar. 2020

COVID-19 Weekly Roundtable 9 For Law Enforcement and Correctional Health Care. Webinar. Major County Sheriffs of America. May 15, 2020.

“Ins and Outs of Healthcare for People Who Are Incarcerated.” Beth Israel Deaconess Medical Center, Aug 20, 2020.

COVID-19 Taskforce Forum Kentucky AIDS Education Training Center. Webinar. May 17, 2020.

“Providing RWHAP Services to People who are Justice-Involved” National Ryan White Conference on HIV Care and Treatment. Webinar. August 2020

2019

“The Intersecting Roles of Primary Care and Infectious Diseases.” Keynote Speaker, Harvard Medical School Infectious Diseases and Primary Care Course, Oct 2019.

“Infectious Diseases Care in Criminal-Legal Involved Populations: Opportunities for Improvement.” MGH HIV Speaker Conference Series. Boston, MA. 2019.

“Where the Rubber Meets the Road: Roadmap to Improving HCV Care in Jails,” Massachusetts Department of Health, May 2019.

“Unlocking HCV Care in Jail: Stakeholders are the Key” Center for AIDS Research Conference, Providence RI, July 2019.

“Who We Are, What We Need: Patient Panel.” Moderator, New England AIDS Education and Training Center Conference. Boston, MA. 2019.

“A 5-Step Guide towards Improving Healthcare for People Who Use Drugs.” Internal Medicine Grand Rounds Penn State Health and College of Medicine. State College, PA. 2019.

“ID Doctors Treating Infections in People Who Use Drugs: What Is Our Next Move? .” HIV Grand Rounds University of Pennsylvania, May 16, 2019.

“Improving Screening and Treatment in Correctional Settings: Lessons from Massachusetts.” IDWeek 2019. Washington DC. October 2019.

2018

“HIV and Justice-Involved Populations,” 24th Annual Meeting, HIV Update: Contemporary Issues in Management, Harvard Medical School and Beth Israel Deaconess Medical Center, May 29 2018

“HCV Treatment Costs: Implications for Patients and Doctors.” 15th Annual Public Health Leadership Forum. Massachusetts Medical Society. Waltham, MA. October 25, 2018

“HCV and Real-World Circumstances” American Liver Foundation BLOCK HIV/HCV Conference. Boston, MA. 2018.

“Facebook Live: Infections in People Who Use Drugs,” Infectious Diseases Society of America, June 2018.

“*Hidden* Casualties: National Partners' Response to the Opioid Epidemic & Infectious Diseases, Health Policy Perspectives” HIV.gov. Webinar. March 2018.

“Acute and Chronic Disease Management in People with Substance Use Disorder” Montana Asthma Control Program. Webinar. 2018.

“Hep B and Hep C” HIV Interprofessional Update, AIDS Education and Training Center, Boston MA 2018

“IDU and Osteoarticular Infections”. Oxford Bone Infection Conference. Oxford, England. March 22, 2018.

“Hep B and Hep C Updates”. HIV Primary Care Conference, New England AIDS Training Center Nashua, NH 2018

2017

“Infections in People Who Use Drugs.: Brigham HIV Conference. Boston MA. November 2017

“HCV Testing and Treatment Pathways in Jails” Tufts CTSI Stakeholder & Community Engagement Symposium, March 2017

“IDU and Osteoarticular Infections.” Musculoskeletal Infection Society. Boston, MA. 2017

“Hep B and Hep C Updates”. New England AIDS Training Coalition. Boston MA. 2017

2016

American Society of Microbiology, Meet the Professor Talk: HCV/HIV Co-infection

Clinical Management of Skin and Soft Tissue Infections in Opioid Users. IDWeek 2016. New Orleans, LA. October 30, 2016

“HCV and Pregnancy”, Obstetrics and Gynecology Grand Rounds, Tufts Medical Center, Nov 2016.

2015

Wurcel AG Curriculum Vitae /Bibliography

“Issues in treating HIV/HCV Co-infected Patients.” HCV and Kidney Diseases New England Consortium, September 2015.

“HIV and PrEP.” AIDS Conference, Whittier Health Center Boston, December 2015

2014

“HIV/HCV Coinfection: What role does the gut play?” Lemuel Shattuck Hospital HIV Conference Boston, MA. March, 2014

“HIV/HCV Update for Community Health Center Providers.” New England AIDS Education and Training Center. Dorchester MA. June 2014

2013

“Women, HIV/AIDS and Hepatitis C. Healing Our Community Collaborative, December 2013

Media Appearances

2021

“Real Talk in the Commonwealth” with Sherriff Tompkins, January 28, 2021

2020

“The Doctors Show” Aired October 27, 2020